Morris C J, Cantrill J A
School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester, UK.
J Clin Pharm Ther. 2003 Aug;28(4):295-305. doi: 10.1046/j.1365-2710.2003.00496.x.
To describe the process that has been undertaken to (i) validate further UK indicators for preventable drug-related morbidity (PDRM) generated by a previous study and (ii) develop additional new indicators derived from UK clinical practice.
A two-round Delphi questionnaire survey.
A UK study based in primary care.
A purposively selected sample of primary care pharmacists (n = 9) and general practitioners (n = 8).
The establishment of consensus among the panel as to whether an indicator represented a PDRM.
The pre-defined level of consensus was achieved for 24 indicators (59%; 24 of 41).
We have identified that although mechanisms exist for identifying 'the outcome' component of PDRM indicators, identifying the 'pattern of care' that is needed to prevent their occurrence is far more challenging. Nonetheless, we have taken considerable steps along the path of validating such indicators. Future operationalization in a general practice setting should help to facilitate improvements in medicine management in primary care and ultimately benefit patients.
描述为以下事项所开展的过程：(i) 进一步验证先前研究生成的英国可预防药物相关发病率（PDRM）指标，以及 (ii) 制定源自英国临床实践的其他新指标。
两轮德尔菲问卷调查。
一项基于英国初级保健的研究。
经过有目的选择的初级保健药剂师样本（n = 9）和全科医生样本（n = 8）。
专家小组就是否某项指标代表可预防药物相关发病率达成共识。
41项指标中的24项（59%；24项）达成了预先定义的共识水平。
我们已确定，尽管存在识别可预防药物相关发病率指标“结果”部分的机制，但识别预防其发生所需的“护理模式”要困难得多。尽管如此，我们在验证此类指标的道路上已迈出了相当大的步伐。未来在全科医疗环境中的实施应有助于促进初级保健中药物管理的改善，并最终使患者受益。
